NCT06578949View on ClinicalTrials.gov

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

May 15, 2025

Study Completion Date

January 14, 2026

Conditions
Paroxysmal Nocturnal HemoglobinuriaPNH
Interventions
DRUG

Ravulizumab

Ravulizumab will be administered by intravenous (IV) infusion.

Trial Locations (8)

200040

Research Site, Shanghai

226001

Research Site, Nantong

300020

Research Site, Tianjin

300050

Research Site, Tianjin

310003

Research Site, Hangzhou

430022

Research Site, Wuhan

510100

Research Site, Guangzhou

CN-100730

Research Site, Beijing

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY